참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Morpholine | HCID 8083 | — |
| 반응물 | 1-Iodo-3-(2-methoxyethoxy)-5-nitro-benzene | HCID 59817811 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | Binap, (A+-)- | HCID 634876 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | 4-[3-(2-Methoxyethoxy)-5-nitrophenyl]morpholine | HCID 59817838 | 53.1% |
반응 단계
The diacetoxypalladium (0.337 g, 1.50 mmol) was added to a stirred mixture of 1-iodo-3-(2-methoxyethoxy)-5-nitrobenzene (9.7 g, 30.02 mmol), cesium carbonate (29.3 g, 90.07 mmol) and morpholine (3.41 mL, 39.03 mmol) and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (1.869 g, 3.00 mmol) dissolved in toluene (200 mL) and dioxane (50 mL) The reaction was degased, purged with argon and heated at 110 °C for 15 hours. The mixture was diluted with dichloromethane (250ml) the salts were fitered, the filtrate was concentrated. The crude product was purified by flash chromatography on silica gel eluting with 0 to 15% ethyl acetate in dichloromethane. The solvent was evaporated to dryness to afford 4-(3-(2-methoxyethoxy)-5-nitrophenyl)morpholine (4.50 g, 53.1 %) as a orange solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-ea00f60c7d1b4b2b96c954e87362056a |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|